Building a Biotech Brand from Series A to IPO: A Life Sciences Branding Playbook

Table of Contents

1. The Short Answer: Why Brand Matters Before You Have a Product on the Market
2. The 4 Stages of Life Sciences Brand Building
3. Stage 1 — Series A: Foundation
4. Stage 2 — Series B/C: Scaling the Brand
5. Stage 3 — Pre-IPO: Investor Readiness
6. Stage 4 — Commercial Launch: Market Entry
7. The Shockwave Medical Story: Brand as a Strategic Asset
8. Other XDS Life Sciences Brand Case Studies
9. Common Branding Mistakes in Regulated Industries
10. Branding for Regulated Industries: FDA Considerations and Scientific Credibility
11. FAQ
12. Start Your Brand Strategy with HueRx Creative

The Short Answer: Why Brand Matters Before You Have a Product on the Market

The most common mistake pre-commercial biotech and medtech companies make is treating brand as something to build after the product is proven. That's backward. Your brand is encountered by investors, employees, partners, key opinion leaders, and future patients before your product is ever in their hands — and the impression it creates in those pre-commercial years either supports or undermines everything that follows.

Investors decide whether to write term sheets based partly on whether a company looks like a legitimate, scalable healthcare enterprise. Top scientists evaluate job offers based on whether the company feels like a place worth spending five years. Strategic partners — including the large pharmaceutical and medtech companies that might acquire you — assess brand as a proxy for organizational maturity.

A weak brand in Series A doesn't just look unprofessional. It actively costs you talent, partnership opportunities, and valuation headroom. This post is a practical guide to building a life sciences brand that earns those opportunities at every stage of company development.

The 4 Stages of Life Sciences Brand Building

Brand strategy in life sciences isn't a one-time project — it's a four-stage buildout that evolves with the company. The capital you've raised, the milestones you're targeting, and the audiences you need to reach determine what belongs in each stage.

Each stage has different time horizons, different budget constraints, and different risk profiles for brand investment. What follows is a breakdown of what each stage actually requires — and where the most common money is left on the table.

Stage 1 — Series A: Foundation

What's Needed

Most Series A biotechs and medtechs close their round with a name, a logo, and a slide deck. That's not a brand — it's a placeholder. Stage 1 brand work builds the foundation that everything else will be layered onto. Skimping here creates expensive rework at Series B and later.

Naming If naming hasn't been resolved, Series A is the time. Life sciences naming has two distinct requirements that consumer and tech naming does not: it must survive a legal clearance search across the USPTO and international trademark registries, and it must be capable of working in regulated contexts — potentially as an approved brand name for a drug or device someday, or at minimum in promotional materials that will go through MLR.

Key naming criteria for life sciences: - Distinctive (not descriptive) — easier to protect legally - No negative connotations in the languages of your target markets - Searchable and memorable (important for HCP digital engagement) - Compatible with potential FDA submission requirements if the name will be used for approved products

Visual Identity The logo, color system, typography, and iconography need to be built to last — or at least to scale without requiring a full rebrand at the next financing round. This means:

• A flexible mark that works across digital, print, and scientific contexts
• A color palette with enough range for an evolving system (single-color companies get squeezed when they need to differentiate therapeutic areas)
• Typography that reads well in scientific tables, regulatory submissions, and marketing materials alike

Brand Positioning and Messaging This is often skipped entirely at Series A, and it shouldn't be. Before you write a word of content, you need a clear positioning statement that answers: What do you do, for whom, and why does it matter in a way that no one else can claim? This becomes the foundation for your investor pitch, your website, your press releases, and eventually your promotional messaging. Building it at Series A means every piece of communication that follows starts from the same place.

Website The Series A website is not a commercial product website — it is a credibility asset and a talent acquisition tool. It needs to convey scientific legitimacy, company vision, team depth, and what problems you're solving. It does not need to convert patients. It does need to perform in search for investors and scientists who will type your company name after hearing about you at a conference.

Minimum viable Series A website: - Science/technology page with accurate, accessible explanations - Pipeline or product page (even pre-clinical stage) - Team page with credentials - Careers page (even if you're only hiring for 2–3 roles) - Press/news section (keeps the site looking active) - Contact and investor inquiry forms

Stage 2 — Series B/C: Scaling the Brand

What's Needed

By Series B, the science is more defined, the team is larger, and the company is beginning to engage external audiences beyond investors. This is where brand investment pays the most dividends relative to cost.

Messaging Architecture A single positioning statement isn't enough anymore. Series B companies need a layered messaging framework: - Core company narrative (why we exist) - Platform or technology messaging (how it works, what makes it different) - Indication-specific messages (for each program in development) - Audience-specific variants (investor vs. HCP vs. patient vs. scientific community)

This architecture keeps all communications aligned as the team grows and more people are producing external content — press releases, scientific publications, conference presentations, social posts, website copy.

HCP-Facing Materials If clinical data is being presented at medical conferences, this is when branded medical affairs materials become necessary. Scientific slide decks, disease state education materials, and conference booth systems need to reflect a mature, credible brand — not clip art and Times New Roman.

Digital Presence Expansion Series B is when digital starts mattering commercially: - LinkedIn company page strategy (important for talent and investor relations) - Publication and conference calendar integration - Email programs for HCP and investor audiences - Beginning of a content strategy (disease state education, clinical data summaries, pipeline updates)

Clinical Trial Recruitment If the company is running clinical trials, patient recruitment digital strategy becomes a brand question. How you present the trial — the language, the design, the digital touchpoints — affects enrollment. See our post on AI clinical trial recruitment for the digital strategy.

Stage 3 — Pre-IPO: Investor Readiness

What's Needed

Pre-IPO is when brand work gets highest-stakes. The S-1 filing creates a permanent public record. Roadshow materials will be seen by hundreds of institutional investors. Media coverage of the IPO will reference your brand identity and messaging. Inconsistency at this stage is visible and costly.

S-1 and Investor Relations Alignment The brand story in your S-1 needs to be consistent with every other public-facing asset. This sounds obvious — but after years of incremental messaging updates, most companies find significant inconsistency between their website, their pitch deck, their press materials, and their regulatory filings. A pre-IPO brand audit and alignment exercise is often the most valuable project in this stage.

Roadshow Materials The IPO roadshow deck is arguably the most read single document a pre-commercial life sciences company produces. It needs to be: - Visually consistent with the brand system - Scientifically clear but investor-accessible - Emotionally compelling (this is still a narrative, not just a data dump) - Consistent in language with the S-1 and press materials

Media Narrative Healthcare journalists, financial media, and industry analysts will be covering the IPO. The brand narrative — the story the company tells about why it exists and why it will win — needs to be developed, tested with stakeholders, and delivered consistently across every channel. An underdeveloped media narrative at IPO gets replaced by whatever the journalists piece together themselves, and that story is rarely as good as the one you should have told.

Digital Infrastructure for a Public Company Post-IPO, you're a public company with different disclosure obligations, investor relations requirements, and visibility expectations. Setting up the digital infrastructure (IR page, EDGAR filing integration, press room, social strategy for public company comms) before the IPO goes live reduces the scramble considerably.

Stage 4 — Commercial Launch: Market Entry

What's Needed

Commercial launch is where the full brand system pays off. The company that has invested in brand foundations at each prior stage has the architecture to move fast. The company that waited until launch to think about brand is buying time — at premium agency rates — while the commercial window is open.

Full Commercial Brand System HCP-facing promotional materials (print and digital), patient-facing materials, sales team tools, website update for commercial indication, paid digital campaigns — all of these need to work from a coherent brand system that has been MLR-reviewed in its foundational elements.

DTC and DTP Marketing If the product supports a DTC or direct-to-patient campaign, brand voice now has to work for a patient audience that may be less scientifically literate than the HCP and investor audiences the brand has been talking to for years. This is a significant voice calibration — and one that needs to happen within the regulatory constraints of promotional messaging.

Payer and IDN-Facing Materials In hospital and health system accounts, materials need to speak to value frameworks: budget impact, outcomes data, formulary positioning. The brand system needs to flex into these contexts without feeling disconnected from the patient and HCP-facing materials.

KOL and Medical Affairs Programs Key opinion leader programs, medical education, and advisory boards all require branded materials that operate in the gray zone between promotional and scientific. Medical affairs materials have different regulatory requirements than promotional materials — a brand system that has been designed with this in mind makes compliance far easier.

The Shockwave Medical Story: Brand as a Strategic Asset

The Shockwave Medical relationship is the clearest demonstration we have of what brand investment does for a life sciences company over time. We've told the full story on our blog — Creating a $13 Billion Dollar Brand — but here is the commercial summary.

When XDS began working with Shockwave, they were a medical device company with a compelling technology (intravascular lithotripsy) and a brand that didn't yet match the ambition of the science. Over a six-year partnership, we built the brand from the ground up and scaled it through every stage of the company's growth:

• Foundation: Positioning, visual identity, and messaging architecture that could support both clinical and investor audiences
• Scale: HCP-facing materials, digital presence, conference systems, and a content strategy that positioned Shockwave as the authority in IVL
• IPO: Brand alignment for the S-1, roadshow materials, and media narrative development for the 2019 IPO
• Post-IPO growth: Full commercial brand system, DTC and HCP campaigns, international expansion

The outcome: 400% increase in lead generation. 40% growth in organic traffic. Gold MarCom Awards for brand work. And in 2024, Johnson & Johnson's $13.1 billion acquisition of Shockwave — at the time one of the largest medtech deals in history.

Brand wasn't the only reason for that outcome. The science was extraordinary, the clinical data was compelling, and the commercial team executed well. But a brand that investors, HCPs, and acquirers found credible, differentiated, and memorable contributed to the premium that a strategic buyer was willing to pay.

Other XDS Life Sciences Brand Case Studies

Shockwave is the headline, but it's not the only story.

PrognomIQ PrognomIQ came to XDS with a name and not much else — no visual identity, no positioning, no website. We built the complete brand from the ground up: naming validation, full identity system, positioning and messaging architecture, and a launch website designed for both scientific and investor audiences. A company that needed to establish credibility with the proteomics community quickly had the brand infrastructure to do it.

Cytokinetics A 25-year-old cardiovascular company with a pipeline that had evolved considerably beyond its original positioning. We led a comprehensive rebrand — including a full identity refresh, messaging architecture overhaul, and website redesign — that positioned Cytokinetics' omecamtiv mecarbil and aficamten programs clearly for HCP and investor audiences ahead of key data readouts.

Recor Medical Recor Medical needed a brand system capable of supporting both their European commercial launch and their U.S. market entry following FDA clearance. We built a flexible system that worked across both markets with appropriate regulatory adaptation.

Iantrek Early-stage ophthalmic device company building a brand foundation ahead of clinical milestones. Our work covered positioning, identity, and investor-facing materials that established credibility with retinal specialists and institutional investors simultaneously.

Each of these engagements reinforces the same principle: brand investment made at the right stage of company development creates leverage. Brand investment made reactively — at a pivot, ahead of an IPO, or at commercial launch — costs more and produces less because there is no foundation to build from.

Common Branding Mistakes in Regulated Industries

These are the patterns we see repeatedly. Most are preventable.

Waiting too long to invest in brand The classic mistake. The team is focused on science, the board wants all capital in R&D, and brand gets deferred to the "next round." By the time the decision is made, the company is in a competitive landscape where every competitor has a more mature brand — and the ramp-up costs more than it would have if done earlier.

Treating brand as just a logo Brand is a strategic system: positioning, messaging, visual identity, verbal identity, and the experiences delivered at every touchpoint. Logos are one element of that system. Companies that invest in logo design without the surrounding brand architecture find that every new piece of communication requires a new set of decisions that should have already been made.

Ignoring digital during pre-commercial Pre-commercial biotech and medtech companies consistently under-invest in digital presence. HCPs research companies before engaging. Investors Google you before meetings. Scientists look at your website before accepting an advisory board invitation. A digital presence that doesn't reflect the quality of your science is a credibility tax you pay constantly.

Not planning for regulatory from the start In regulated industries, some brand decisions have regulatory implications — product names, claims language, the presentation of clinical data in marketing materials. Brand systems that aren't designed with FDA promotional guidelines and MLR workflow in mind get expensive to adapt later. Building regulatory awareness into brand strategy from the beginning is not a constraint — it's risk management.

Generic scientific positioning "We are developing novel therapies to address unmet medical needs" is not a brand position. It is a description of the entire pharmaceutical industry. The companies that achieve premium valuations and premium talent attraction have a specific, defensible, memorable point of difference. Finding that point of difference requires real strategic work — not a one-day offsite with a consultant.

Building brand in isolation from commercial strategy Brand strategy that isn't integrated with the commercial go-to-market strategy produces beautiful assets that don't drive commercial outcomes. The brand needs to be built around how you will reach and convert HCPs, how sales will position against competitors, and what the patient experience will be at the point of diagnosis and prescription. Those are commercial strategy questions — and brand strategy should be answering them.

Branding for Regulated Industries: FDA Considerations and Scientific Credibility

Life sciences brand work operates under regulatory constraints that most branding agencies are not equipped to navigate. These are the most important considerations.

FDA and FTC promotional guidelines Once you have an approved product, every piece of marketing communication is subject to FDA promotional guidelines (for drugs and devices) and FTC standards for truthfulness. Brand systems need to be designed with these constraints in mind: - Claims language must be substantiated and consistent with the approved label - ISI and PI requirements affect design (how materials present safety information) - Off-label messaging is strictly prohibited in promotional materials - Comparative claims against competitors require specific substantiation

The scientific credibility vs. approachability balance Life sciences brand design often falls into one of two traps: either it looks so clinical that it repels non-scientific audiences (patients, investors, the general press), or it looks so consumer-friendly that it loses credibility with HCPs and scientific reviewers. The brands that work — in life sciences and in healthcare more broadly — achieve both. They use language and visual design that signals scientific rigor while remaining accessible to the audience at hand.

Medical-Legal-Regulatory (MLR) workflow integration Pre-commercial companies often have loose or informal MLR processes because they're not yet running promotional campaigns. But every piece of external communication — investor materials, website copy, press releases, conference presentations — benefits from MLR review. Building a lightweight MLR workflow early, before the volume demands a full system, prevents the accumulation of unapproved claims that become expensive to remediate.

ISI and PI integration in commercial design When commercial promotion begins, design templates need to be built with ISI and PI integration as a design constraint, not an afterthought. The companies that treat safety information as a design problem to be solved produce better materials — more readable, more compliant, and better received by HCPs — than the companies that bolt ISI onto the bottom of existing designs.

At HueRx Creative, this is foundational to how we approach brand design. We build regulatory requirements into brand systems — so the teams using them can move fast without creating compliance debt.

For more on the broader marketing strategy context, see our posts on medtech marketing strategy and healthcare website redesign.

FAQ

Q: When should a biotech company start investing in brand strategy?

A: At Series A, or earlier if resources allow. The Series A is when you're actively fundraising, hiring senior team members, presenting at conferences, and forming strategic partnerships — every one of those interactions is a brand interaction. Entering Series A with positioning that isn't clearly differentiated and a website that looks like it was designed in 2018 is a preventable liability.

Q: How much should a pre-commercial biotech spend on brand?

A: For a Series A company, a credible brand foundation — name validation (if needed), visual identity, positioning, messaging, and website — typically runs $80,000–$250,000 depending on scope and complexity. This sounds significant against a $10–20M Series A, but it is a rounding error relative to the valuation premium that a mature brand generates at subsequent rounds and at exit. The more useful framing: what is the cost of looking less credible than your competitors to the investors you're trying to impress?

Q: Can we just update our brand at pre-IPO instead of building it earlier?

A: Technically yes, but it costs significantly more and you bear the risk of having an under-branded company during the years when you're most actively competing for talent, partners, and investment. Pre-IPO brand work is also more constrained — by this point you have extensive published materials, conference history, and potentially SEC filings in process that limit how dramatically you can change positioning or identity. Building a strong foundation earlier gives you the flexibility to evolve without having to start over.

Q: How do you build a brand that works for both investors and patients?

A: The answer is audience architecture: different layers of the brand system speak to different audiences, but all emerge from the same strategic foundation. The corporate brand is investor- and partner-facing. The therapeutic or product brand speaks to HCPs and patients. Both can coexist within a coherent brand system if the positioning and messaging architecture are designed to support it. Companies that try to do both with a single, undifferentiated brand often end up speaking effectively to neither audience.

Q: What's the most important brand asset for a pre-commercial life sciences company?

A: The positioning statement and messaging architecture — not the logo. Visual identity is important, but it is the expression of the strategy, not the strategy itself. The companies that invest in rigorous positioning work first find that everything downstream (website copy, investor presentations, scientific abstracts, media coverage) is easier and more consistent. The companies that start with visual design and try to reverse-engineer the strategy into it pay for alignment work every time a new piece of communication is needed.

Q: How is biotech branding different from general pharmaceutical branding?

A: Biotech brands at early stage are more investor-facing, more science-forward, and more dependent on narrative storytelling about platform technology rather than individual approved products. Traditional pharma branding (for an approved drug) is heavily regulated at the promotional level and focused on HCP and patient audiences. Biotech brand strategy must navigate both: building credibility with scientific and investor audiences pre-commercially while building the foundation for product-level promotion at approval. The brand architecture needs to support both modes.

Q: Does brand matter for an acquisition outcome?

A: Yes, measurably. Strategic acquirers assess brand as a proxy for organizational maturity, commercial readiness, and integration complexity. A company with a weak, inconsistent brand requires more integration work post-acquisition — a cost that sophisticated acquirers factor into valuation. Beyond the financial mechanics, brand quality affects whether key personnel stay post-acquisition, whether HCP relationships transfer, and how quickly the combined commercial organization can go to market. The Shockwave Medical acquisition is the clearest example in our portfolio: a strong, mature brand contributed to the premium that Johnson & Johnson was willing to pay.

Start Your Brand Strategy with HueRx Creative

HueRx Creative is XDS's dedicated life sciences brand studio — built for biotech, medtech, pharma, and diagnostics companies that need brand strategy and design that operates within regulatory reality.

Our work spans the full brand lifecycle: from naming and positioning at Series A through commercial brand systems at product launch and post-approval campaigns. Our portfolio includes work across oncology, cardiovascular, ophthalmology, diagnostics, and rare disease — built to perform with investors, HCPs, patients, and the scientific community.

Schedule a brand strategy consultation →

We'll review where your brand is today, identify the gaps that are most likely to cost you at the next milestone, and outline what it would take to close them. For companies in active fundraising, we can often turn around foundational brand work in compressed timelines.

You can also explore XDS Health for our full life sciences marketing portfolio, or review our thinking on how to choose the right healthcare marketing agency if you're earlier in the evaluation process.